INMED PHARMACEUTICALS INC (INM) Stock Fundamental Analysis

NASDAQ:INM • CA4576377002

0.8901 USD
-0.1 (-10.09%)
At close: Feb 12, 2026
0.8497 USD
-0.04 (-4.54%)
Pre-Market: 2/13/2026, 8:00:41 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

INM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While INM seems to be doing ok healthwise, there are quite some concerns on its profitability. INM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year INM has reported negative net income.
  • INM had a negative operating cash flow in the past year.
  • INM had negative earnings in each of the past 5 years.
  • In the past 5 years INM always reported negative operating cash flow.
INM Yearly Net Income VS EBIT VS OCF VS FCFINM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

  • INM has a Return On Assets of -61.46%. This is in the lower half of the industry: INM underperforms 65.97% of its industry peers.
  • INM has a Return On Equity (-70.84%) which is in line with its industry peers.
Industry RankSector Rank
ROA -61.46%
ROE -70.84%
ROIC N/A
ROA(3y)-57.88%
ROA(5y)-84.67%
ROE(3y)-69.96%
ROE(5y)-110.59%
ROIC(3y)N/A
ROIC(5y)N/A
INM Yearly ROA, ROE, ROICINM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

  • With a Gross Margin value of 33.69%, INM perfoms like the industry average, outperforming 59.16% of the companies in the same industry.
  • INM's Gross Margin has declined in the last couple of years.
  • INM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.34%
GM growth 5YN/A
INM Yearly Profit, Operating, Gross MarginsINM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • INM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, INM has more shares outstanding
  • Compared to 5 years ago, INM has more shares outstanding
  • There is no outstanding debt for INM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INM Yearly Shares OutstandingINM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M
INM Yearly Total Debt VS Total AssetsINM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of -12.39, we must say that INM is in the distress zone and has some risk of bankruptcy.
  • INM's Altman-Z score of -12.39 is on the low side compared to the rest of the industry. INM is outperformed by 75.92% of its industry peers.
  • There is no outstanding debt for INM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.39
ROIC/WACCN/A
WACC8.62%
INM Yearly LT Debt VS Equity VS FCFINM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

2.3 Liquidity

  • INM has a Current Ratio of 6.95. This indicates that INM is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 6.95, INM is doing good in the industry, outperforming 70.68% of the companies in the same industry.
  • A Quick Ratio of 6.37 indicates that INM has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 6.37, INM is in the better half of the industry, outperforming 69.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.95
Quick Ratio 6.37
INM Yearly Current Assets VS Current LiabilitesINM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • INM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.60%, which is quite impressive.
  • Looking at the last year, INM shows a decrease in Revenue. The Revenue has decreased by -3.27% in the last year.
  • INM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 65.52% yearly.
EPS 1Y (TTM)48.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.86%
Revenue 1Y (TTM)-3.27%
Revenue growth 3Y65.52%
Revenue growth 5YN/A
Sales Q2Q%-11.43%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INM Yearly Revenue VS EstimatesINM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 1M 2M 3M 4M
INM Yearly EPS VS EstimatesINM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 -200 -400 -600

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • INM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INM Price Earnings VS Forward Price EarningsINM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INM Per share dataINM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • INM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INMED PHARMACEUTICALS INC

NASDAQ:INM (2/12/2026, 8:00:02 PM)

Premarket: 0.8497 -0.04 (-4.54%)

0.8901

-0.1 (-10.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-10
Earnings (Next)05-11
Inst Owners13.69%
Inst Owner Change-3.25%
Ins Owners0.15%
Ins Owner Change0%
Market Cap2.49M
Revenue(TTM)4.80M
Net Income(TTM)-8.21M
Analysts45
Price TargetN/A
Short Float %4.38%
Short Ratio0.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.52
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 0.25
EV/EBITDA N/A
EPS(TTM)-7.21
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2.7
FCFYN/A
OCF(TTM)-2.7
OCFYN/A
SpS1.71
BVpS4.14
TBVpS3.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.46%
ROE -70.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.69%
FCFM N/A
ROA(3y)-57.88%
ROA(5y)-84.67%
ROE(3y)-69.96%
ROE(5y)-110.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.34%
GM growth 5YN/A
F-Score5
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.95
Quick Ratio 6.37
Altman-Z -12.39
F-Score5
WACC8.62%
ROIC/WACCN/A
Cap/Depr(3y)28.08%
Cap/Depr(5y)21.06%
Cap/Sales(3y)1.36%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.86%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.27%
Revenue growth 3Y65.52%
Revenue growth 5YN/A
Sales Q2Q%-11.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.98%
OCF growth 3YN/A
OCF growth 5YN/A

INMED PHARMACEUTICALS INC / INM FAQ

What is the ChartMill fundamental rating of INMED PHARMACEUTICALS INC (INM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to INM.


What is the valuation status for INM stock?

ChartMill assigns a valuation rating of 0 / 10 to INMED PHARMACEUTICALS INC (INM). This can be considered as Overvalued.


Can you provide the profitability details for INMED PHARMACEUTICALS INC?

INMED PHARMACEUTICALS INC (INM) has a profitability rating of 1 / 10.


How financially healthy is INMED PHARMACEUTICALS INC?

The financial health rating of INMED PHARMACEUTICALS INC (INM) is 6 / 10.